Skip to content
drillr.ai

PSNL

Personalis, Inc.

NASDAQ · USHealthcareMedical - Diagnostics & Research
$13.34-13.32%

Price as of Jul 20, 2026

PSNL news

Personalis, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders

    PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be

    Business Wire ·

  2. PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

    NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner. For a free consultation, please visit https://julieholleman.com/personalis-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. Personalis is a precision oncol

    Globe Newswire ·

  3. Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders

    Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, July 20, 2026 MILWAUKEE, July 20, 2026 /PRNewswire/ -- Ademi LLP is investigating Personalis (NASDAQ: PSNL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Tempus. Click here (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4734808-1&h=475618586&u=https%3A%2F%2Fwww.ademilaw.com%2Fcase%2Fperson

    PR Newswire ·

  4. Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

    Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunity

    Business Wire ·

  5. Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

    Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain Regulatory milestone for the NeXT Personal® Dx test enables clinical use of Personalis’ ultrasensitive MRD detection in Great Britain Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulat

    Business Wire ·

  6. Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

    Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 * NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery * Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Onco

    Business Wire ·

  7. Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

    Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring Expanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic

    Business Wire ·

  8. Personalis to Announce First Quarter 2026 Financial Results

    Personalis to Announce First Quarter 2026 Financial Results Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by diali

    Business Wire ·

  9. Personalis to Participate in the 25th Annual Needham Virtual Conference

    Personalis to Participate in the 25th Annual Needham Virtual Conference Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care th

    Business Wire ·

  10. Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

    Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Ch

    Business Wire ·

  11. Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

    Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease (https://cts.busine

    Business Wire ·